Leptomeningeal Disease clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 18 years and up
A phase 2 non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab with capecitabine for the treatment of leptomeningeal metastases in HER2-neu positive breast cancer.
San Francisco, California and other locations